Welcome to our dedicated page for Corvex news (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Corvex stock.
Corvex, Inc. reports developments in AI cloud computing and GPU-accelerated infrastructure for artificial intelligence workloads. Company news has centered on secure compute clusters, high-throughput storage, managed Kubernetes architecture, confidential computing for data in use, and Secure Model Weights for protected AI inference on third-party GPU infrastructure.
Updates also cover customer deployments, long-term GPU infrastructure arrangements, earnings calls, operating and financial results, and capital-structure actions. Corvex became the public company operating under MOVE after the completed combination with Corvex Legacy Holdings and the name change from Movano Inc. in March 2026.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Movano Inc. (NASDAQ: MOVE), operating as Movano Health, will report its first quarter 2023 financial and operating results on May 15, 2023. Management will host a conference call at 9:00 a.m. PDT (12:00 p.m. EDT) to discuss these results and provide a business update.
The company focuses on developing healthcare solutions that merge medical-grade data with consumer health devices to empower users in managing their health. Their product, the Evie Ring, aimed specifically at women's health, is set to launch in summer 2023. Interested parties can access the live webcast or conference call through the company’s investor relations website.
Movano Health (Nasdaq: MOVE) reported its Q4 and full-year 2022 financial results, revealing a net loss of $7.9 million for Q4, compared to $6.3 million in Q4 2021. For the year, the net loss was $30.3 million, consistent with the previous year. The company is preparing for the summer 2023 launch of its first product, the Evie Ring, and is conducting beta tests with multiple partners. Movano Health has filed for FDA clearance and has received nine new U.S. patents for its non-invasive monitoring technologies. The company ended 2022 with $10.8 million in cash. Additionally, it raised $7.5 million in a recent public offering to support product development.
Movano Health (NASDAQ: MOVE) has secured three new patents for its radio frequency (RF) technology aimed at enhancing health monitoring capabilities. The newly issued patents increase Movano's intellectual property portfolio to 21 patents issued and 38 pending. Notably, these patents focus on monitoring critical health metrics such as blood glucose levels, blood pressure, and heart rate. The proprietary System-on-a-Chip (SoC) allows for improved accuracy and compact device design. The SoC is set for clinical testing in March 2023, with future integration planned for Movano's wearables.
Movano Health's recent survey of 1,000 U.S. women highlights the importance of data accuracy in wearable health devices. With plans for FDA clearance of its Evie Ring, Movano aims to enhance consumer trust in health data. The survey revealed that 65% of participants prioritize FDA approval for wellness metrics, emphasizing the need for reliable data to communicate with healthcare providers. While many women are interested in wearables for health management, accuracy remains a key concern. Movano seeks to position itself in the market by providing highly accurate health insights to address these needs.